Article
Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2021
Levin Noam, Paria Biman C, Vale Nolan R, Yossef Rami, Lowery Frank J, Parkhurst Maria R, Yu Zhiya, Florentin Maria, Cafri Gal, Gartner Jared J, Shindorf Mackenzie L, Ngo Lien T, Ray Satyajit, Kim Sanghyun P, Copeland Amy R, Robbins Paul F, Rosenberg Steven A
Abstract excerpt
PURPOSE: Immunotherapies mediate the regression of human tumors through recognition of tumor antigens by immune cells that trigger an immune response. Mutations in the RAS oncogenes occur in about 30% of all patients with cancer. These mutations play an important role in both tumor establishment and survival and are commonly found in hotspots. Discovering T-cell receptors (TCR) that recognize shared mutated RAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.